JMP Securities downgraded Sana Biotechnology (SANA) to Market Perform from Outperform without a price target after the company announced a portfolio reprioritization. The firm cites uncertainty associated with the company’s various data readouts for the downgrade. It now sees Sana shares as fairly valued.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter